Inhibition of suppressor T lymphocytes (Ts) by cimetidine.
Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC.
J Immunol. 1987 May 1;138(9):2760-3.
PMID: 2952721
Cyclophosphamide (CY) is the most extensively studied inhibitor of suppressor T lymphocyte (Ts) function. However, repeated administration of CY can abrogate sensitization. Therefore, we were interested in identifying noncytotoxic inhibitors of Ts function as adjuncts in the immunotherapy of Ts-inducing murine tumors. The effect of cimetidine (a histamine type 2 receptor antagonist) and diphenhydramine (a histamine type 1 receptor antagonist) on the Ts mediating tolerance to 2,4-dinitrofluorobenzene was studied. We report our data regarding the specific inhibition of Ts by cimetidine.
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN.
J Dtsch Dermatol Ges. 2008 Dec;6(12):1066-9. English, German.
PMID: 19138272
DOI: 10.1111/j.1610-0387.2008.06861.x
The in vitro study, reported in the journal Carcinogenesis (Vol. 27, pp. 32-42), showed that vitamin D, in the form of the highly active 1alpha, 25-dihydroxyvitamin D3 (1,25-VD), inhibited the function of protease enzymes that are involved in tumour invasion.
"We found that 1,25-VD decreased matric metalloproteinases (MMP-9) and cathepsins (CPs), while it [also] increased the activity of their counterparts, tissue inhibitors of metalloproteinase-1 (TIMP-1) and cathepsin inhibitors," wrote lead author Bo-Ying Bao from the University of Rochester and Taipei Medical University.
"Mechanistic studies showed that 1,25-VD did not suppress MMP-9 expression at the transcriptional level, but reduced its mRNA stability," said Bao.
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H.
J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15.
PMID: 19501932
CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21.
PMID: 18645193
DOI: 10.1200/JCO.2007.15.9749
"SCIENTISTS have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. "
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE.
Oral Oncol. 2009 Oct;45(10):e155-60. Epub 2009 Jul 7.
PMID: 19586795
If angiogenesis controls cancer growth, what controls angiogenesis? Researchers at the University of Michigan and the University of South Florida believe that the copper status is critical to the function growth factors.
For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. Using a mouse model of breast cance
A collaborative study led by UCL (University College London) shows that the compound - inositol pentakisphosphate - found in beans, nuts and cereals inhibits a key enzyme (phosphoinositide 3-kinase) involved in tumour growth. The findings, published in the latest issue of Cancer Research, suggest that a diet enriched in such foods could help prevent cancer, while the inhibitor offers a new tool for anti-cancer therapy.
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM.
Clin Cancer Res. 2004 Sep 1;10(17):5930-9.
PMID: 15355926
WARNING: This page was NOT created or approved by any doctor or medical researcher. The purpose of this page is to provide hard-to-find information on copper reduction cancer treatment, a new unapproved and experimental course of cancer treatment whose ef
The article is written by lay individuals for information purposes only and is not to be used to diagnose or treat any disease. The document outlines therapeutic strategies which have not been clinically proven and may not be effective for lymphoma and ot
Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, G. J. Brewer, and S. D. Merajver
Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis
Canc
Brewer GJ, Merajver SD.
Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.
PMID: 14664727 [PubMed - indexed for MEDLINE]
B. G. Redman, P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer, and S. D. Merajver
Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer
Clin. Cancer Res., May 1, 2003; 9(5): 1666 - 1672.
C. Cox, S. D. Merajver, S. Yoo, R. D. Dick, G. J. Brewer, J. S.-J. Lee, and T. N. Teknos
Inhibition of the Growth of Squamous Cell Carcinoma by
Tetrathiomolybdate-Induced Copper Suppression in a Murine Model
Arch Otolaryngol Head Neck Surg, July 1, 200
Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD.
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.
Mol Cancer Ther. 2003 Jul;2(7):617-22.
PMID: 12883034 [PubMed - indexed for MEDLINE]